Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Sponsor
Baohui Han
Study ID
NCT01217619
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib — DRUG
    erlotinib 150mg/d continuously for 56 days

Study Details

This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR mutation in exon 19 or 21.

Key Dates

First listed
Oct 8, 2010
Start date
Mar 2, 2011
Status verified
Sep 2017
Primary completion
Jun 30, 2016
Completion
Oct 30, 2016

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    Single-arm

Primary Outcome Measure

radical resection rate [ Time Frame: operation after effective neoadjuvant treatment of tarceva for 56 days ]

Related Studies